Ubiquitin-Proteasome Genes and Cisplatin Sensitivity in Yeast
Author Information
Author(s): Gatti Laura, Hoe Kwang L, Hayles Jacqueline, Righetti Sabina C, Carenini Nives, Bo Laura Dal, Kim Dong U, Park Han O, Perego Paola
Primary Institution: Fondazione IRCCS, Istituto Nazionale per lo Studio e la Cura dei Tumori
Hypothesis
The study investigates the role of ubiquitin-proteasome pathway genes in modulating sensitivity to cisplatin in fission yeast.
Conclusion
The study identifies specific ubiquitin-proteasome genes that influence cisplatin sensitivity, suggesting potential targets for overcoming drug resistance in cancer treatment.
Supporting Evidence
- Three Ub-proteasome mutants were found to be hypersensitive to cisplatin.
- Ten mutants were identified as resistant to cisplatin.
- The study highlights the relationship between the Ub-proteasome system and DNA damage response mechanisms.
Takeaway
Researchers looked at yeast to see how certain genes affect how well a cancer drug works, finding some genes that make the drug work better and others that make it less effective.
Methodology
The study used a genome-wide screening of non-essential haploid deletion mutants of Schizosaccharomyces pombe to assess sensitivity to cisplatin.
Limitations
The study primarily focuses on yeast models, which may not fully replicate human cancer responses.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website